Assess comparative first-line treatments for driver gene-negative NSCLC with liver metastases using a Bayesian network meta-analysis of randomized trials.
Key Takeaways
- PD-1 inhibitor plus chemotherapy reduced progression risk versus chemotherapy alone (HR 0.572)
- Combination also lowered overall mortality versus chemotherapy alone (HR 0.681)
- Camrelizumab plus chemotherapy had top SUCRA values for PFS (84.18%) and OS (96.38%)